BioNTech SE Sponsored ADR $BNTX Shares Sold by Capital International Inc. CA

Capital International Inc. CA reduced its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 273,073 shares of the company’s stock after selling 20,135 shares during the quarter. Capital International Inc. CA’s holdings in BioNTech were worth $25,997,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. Dodge & Cox raised its stake in BioNTech by 315.7% during the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock worth $359,676,000 after acquiring an additional 2,769,654 shares in the last quarter. BNP Paribas Financial Markets raised its stake in BioNTech by 43.0% during the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares in the last quarter. Bank of America Corp DE raised its stake in BioNTech by 344.4% during the 3rd quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock worth $56,544,000 after acquiring an additional 444,332 shares in the last quarter. SG Americas Securities LLC raised its stake in BioNTech by 1,664.6% during the 4th quarter. SG Americas Securities LLC now owns 365,333 shares of the company’s stock worth $34,780,000 after acquiring an additional 344,630 shares in the last quarter. Finally, Millennium Management LLC raised its stake in BioNTech by 910.3% during the 3rd quarter. Millennium Management LLC now owns 246,327 shares of the company’s stock worth $24,293,000 after acquiring an additional 276,727 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently commented on BNTX. Morgan Stanley lifted their price target on shares of BioNTech from $125.00 to $126.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. Truist Financial upgraded shares of BioNTech to a “strong-buy” rating in a research note on Wednesday, March 25th. TD Cowen lowered their price objective on shares of BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research report on Wednesday, March 11th. HC Wainwright reissued a “buy” rating and set a $130.00 price objective on shares of BioNTech in a research report on Monday, April 27th. Finally, UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $117.00 to $135.00 in a research report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $129.56.

BioNTech Stock Performance

Shares of BioNTech stock opened at $88.08 on Monday. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The company has a market capitalization of $22.27 billion, a P/E ratio of -14.98 and a beta of 1.33. The company’s fifty day moving average is $94.54 and its two-hundred day moving average is $98.87.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($0.39) earnings per share (EPS) for the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%.The business had revenue of $1.06 billion for the quarter. Analysts forecast that BioNTech SE Sponsored ADR will post -4.66 earnings per share for the current year.

BioNTech announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at BioNTech

In other news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at $44,156,226.72. The trade was a 11.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.